3rd ALS Drug Development Summit 2024

Identify Transformative ALS Targets, Seek Translational Biomarkers and Propel More Clinical Approvals

Following monumental progress in 2023, the ALS treatment landscape is surging with novel innovation to navigate the complex, multifactorial nature of motor neuron degeneration and develop more truly transformative drugs for sporadic and familial ALS.

Capitalizing on rapid pipeline progress and emerging industry investment, the 3rd Annual ALS Drug Development Summit returns to Boston, providing a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.

This May, join your industry colleagues across discovery, preclinical, clinical, regulatory, and commercial from the likes of Biogen, Amylyx, AbbVie, NeuroSense, Mitsubishi, Sanofi, Takeda, Novartis, and more.

URLs:
Website: https://go.evvnt.com/2215799-0?pid=176 
Tickets: https://go.evvnt.com/2215799-2?pid=176 
Brochure: https://go.evvnt.com/2215799-3?pid=176 

Time: 8:00 AM - 5:00 PM

Prices:
Industry Pricing - Conference + Workshop Day: USD 3597.00,
Industry Pricing - Conference Only: USD 2599.00,
Service Provider Pricing - Conference + Workshop Day: USD 5197.00,
Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Diego Cadavid Chief Medical Officer Verge Genomics, Disha Sood Senior Scientist Sanofi , Emily Caporello Director, Small Business Program NINDS/NIH , Emma Bowden Vice President and Head of Clinical Development QurAlis Corp. , Fen Huang Director - Translational Sciences Denali Therapeutics Inc. , Fred Grossman President and Chief Medical Officer Coya Therapeutics , Howard Rutman Chief Medical Officer Xalud Therapeutics , Karen King Member Genetic ALS and FTD: End the Legacy , Lahar Mehta Vice President and Head of Global Clinical Development Amylyx Pharmaceuticals Corp. , Layne Oliff Advocate I AM ALS Laynie Dratch Genetic Counselor Penn Medicine , Machelle Manuel VP and Global Head Medical Affairs Amylyx Pharmaceuticals Corp. , Mansuo Lu Shannon Chief Scientific Officer Prevail Therapeutics , Marjan Sepassi Vice President - Medical Affairs Clene Nanomedicine , Mary Kay Turner Senior Vice President, Global Patient Advocacy and Public Affairs BrainStorm Cell Therapeutics , Neil Shneider Director The Eleanor and Lou Gehrig ALS Center, Columbia University , Neta Zach Head of Neuroscience Experimental Medicine Takeda Pharmaceutical Co. Ltd. , Paul Wicks Advocate Independent , Paul Wright Head of Motor Neuron Disease Translational Challenge LifeArc , Petra Duda Senior Executive Director - Clinical Research and Global Development Lead UCB Pharma , Philip Wong Professor Johns Hopkins University , Robert Bowser Chief Scientific Officer Barrow Neurological Institute , Sabrina Paganoni Co-Director - Neurological Clinical Research Institute Massachusetts General Hospital (MGH) and Harvard Medical School , Sakshi Sardar Senior Scientific Director, Digital and Precision Medicine Critical Path Institute , Sarah Luppino Nurse Practitioner and Healey and AMG Center for ALS Research Site Director Massachusetts General Hospital (MGH) and Harvard Medical School , Sharon Tamir Digital Healthcare Innovation, Business and Research Strategy Mitsubishi Tanabe Pharma , Shih-Ching (Joyce) Lo Associate Director Biogen , Shiran Zimri Vice President of Research and Development NeuroSense Therapeutics , Sophie Parmentier-Batteur Head of Neurodegeneration Novartis , Stacy Lindborg Co- CEO BrainStorm Cell Therapeutics , Tao Yang Director - Computational Biology Prevail Therapeutics , Wen-Hsuan Chang Head of Target Validation AcuraStem Inc. , Yuqiang Wang Chief Executive Officer Magpie Pharmaceuticals, Aarti Sharma Associate Director Regeneron Pharmaceuticals Inc , Akinori Hishiya CSO SOLA Biosciences , Angela Genge Chief Medical Officer QurAlis Corp. , Arti Patel Principle Scientist II Novartis AG , Barbara Nguyen-Vu Senior Director - Neuroscience MeiraGTx , Bijan Nejadnik Head Of Global Development, Regulatory Affairs and Quality Assurance Mitsubishi Tanabe Pharma , Christopher Ocampo Senior Medical Director Abbvie , Collin Hovinga Vice President of Rare and Orphan Diseases Critical Path Institute